MRPL35 Induces Proliferation, Invasion, and Glutamine Metabolism in NSCLC Cells by Upregulating SLC7A5 Expression

被引:8
作者
Hou, Wei [1 ]
Chen, Juan [1 ]
Wang, Yaoyuan [1 ]
机构
[1] Shaanxi Prov Nucl Ind 215 Hosp, Resp Dept, Xianyang, Peoples R China
关键词
deubiquitination; glutamine metabolism; MRPL35; USP39; MITOCHONDRIAL; GROWTH;
D O I
10.1111/crj.13799
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BackgroundMitochondrial ribosomal protein L35 (MRPL35) has been reported to contribute to the growth of non-small cell lung cancer (NSCLC) cells. However, the functions and mechanisms of MRPL35 on glutamine metabolism in NSCLC remain unclear.MethodsThe detection of mRNA and protein of MRPL35, ubiquitin-specific protease 39 (USP39), and solute carrier family 7 member 5 (SLC7A5) was conducted using qRT-PCR and western blotting. Cell proliferation, apoptosis, and invasion were evaluated using the MTT assay, EdU assay, flow cytometry, and transwell assay, respectively. Glutamine metabolism was analyzed by detecting glutamine consumption, alpha-ketoglutarate level, and glutamate production. Cellular ubiquitination analyzed the deubiquitination effect of USP39 on MRPL35. An animal experiment was conducted for in vivo analysis.ResultsMRPL35 was highly expressed in NSCLC tissues and cell lines, and high MRPL35 expression predicted poor outcome in NSCLC patients. In vitro analyses suggested that MRPL35 knockdown suppressed NSCLC cell proliferation, invasion, and glutamine metabolism. Moreover, MRPL35 silencing hindered tumor growth in vivo. Mechanistically, USP39 stabilized MRPL35 expression by deubiquitination and then promoted NSCLC cell proliferation, invasion, and glutamine metabolism. In addition, MRPL35 positively affected SLC7A5 expression in NSCLC cells in vitro and in vivo. Moreover, the anticancer effects of MRPL35 silencing could be rescued by SLC7A5 overexpression in NSCLC cells.ConclusionMRPL35 expression was stabilized by USP39-induced deubiquitination in NSCLC cells, and knockdown of MRPL35 suppressed NSCLC cell proliferation, invasion, and glutamine metabolism in vitro and impeded tumor growth in vivo by upregulating SLC7A5, providing a promising therapeutic target for NSCLC. SLC7A5 overexpression reversed MRPL35 knockdown-caused inhibition of NSCLC cell growth, invasion, glutamine metabolism, and induction of cell apoptosis.image
引用
收藏
页数:11
相关论文
共 32 条
[1]   From Krebs to clinic: glutamine metabolism to cancer therapy [J].
Altman, Brian J. ;
Stine, Zachary E. ;
Dang, Chi V. .
NATURE REVIEWS CANCER, 2016, 16 (10) :619-634
[2]   Glutamine metabolism in diseases associated with mitochondrial dysfunction [J].
Bornstein, Rebecca ;
Mulholland, Michael T. ;
Sedensky, Margaret ;
Morgan, Phil ;
Johnson, Simon C. .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2023, 126
[3]   Is mitochondrial generation of reactive oxygen species a trigger for autophagy? [J].
Chen, Yongqiang ;
Gibson, Spencer B. .
AUTOPHAGY, 2008, 4 (02) :246-248
[4]   Breaking the chains: deubiquitylating enzyme specificity begets function [J].
Clague, Michael J. ;
Urbe, Sylvie ;
Komander, David .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (06) :338-352
[5]   Role of mitochondrial dysfunction in cancer progression [J].
Hsu, Chia-Chi ;
Tseng, Ling-Ming ;
Lee, Hsin-Chen .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 241 (12) :1281-1295
[6]   MRPL42 is activated by YY1 to promote lung adenocarcinoma progression [J].
Jiang, Wei ;
Zhang, Chengpeng ;
Kang, Yunteng ;
Yu, Xiaojun ;
Pang, Pei ;
Li, Guangbin ;
Feng, Yu .
JOURNAL OF CANCER, 2021, 12 (08) :2403-2411
[7]   Targeting glutamine metabolism as a therapeutic strategy for cancer [J].
Jin, Jonghwa ;
Byun, Jun-Kyu ;
Choi, Yeon-Kyung ;
Park, Keun-Gyu .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2023, 55 (04) :706-715
[8]   MRPL13 Act as a Novel Therapeutic Target and Could Promote Cell Proliferation in Non-Small Cell Lung Cancer [J].
Jing, Chuanqing ;
Fu, Rong ;
Wang, Can ;
Li, Xiurong ;
Zhang, Wei .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :5535-5545
[9]   Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer [J].
Kurozumi, Sasagu ;
Kaira, Kyoichi ;
Matsumoto, Hiroshi ;
Kurosumi, Masafumi ;
Yokobori, Takehiko ;
Kanai, Yoshikatsu ;
Sekine, Chikako ;
Honda, Chikako ;
Katayama, Ayaka ;
Furuya, Mio ;
Shiino, Sho ;
Makiguchi, Takaya ;
Mongan, Nigel P. ;
Rakha, Emad A. ;
Oyama, Tetsunari ;
Fujii, Takaaki ;
Shirabe, Ken ;
Horiguchi, Jun .
SCIENTIFIC REPORTS, 2022, 12 (01)
[10]   Molecular targeted therapy: Treating cancer with specificity [J].
Lee, Yeuan Ting ;
Tan, Yi Jer ;
Oon, Chern Ein .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 834 :188-196